No Data
No Data
AstraZeneca: Strong Sales and Robust Pipeline Underpin Buy Rating
Eli Lilly and Co (LLY.US) explores new uses for "miracle weight-loss drug" Zepbound, aiming to reduce the incidence of diabetes and other high-risk populations.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Daiichi Sankyo/AstraZeneca (AZN.US) heavy-duty ADC obtains FDA priority review qualification.
The USA FDA is expected to complete the review in the first quarter of 2025.
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
AstraZeneca Updates Share Voting Rights
No Data
No Data
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.